sellWeak10b5-1 plan
Christopher Heery sold $993k of ACLX
CHIEF MEDICAL OFFICER at Arcellx, Inc.. 12,396 shares at an average of $80.12, traded Sep 26, 2025, filed Sep 26, 2025.
Warning score
30Value
$993k
12,396 shares
Holdings after
21,731
-36% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
- +15RoleOfficer
- +25Trade size$993k at market
- +10Share of holdings soldSold 36% of holdings
- 0ClusterNo other insider selling within 14 days
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0001193125-25-220970, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Sep 26, 2025 | SOpen-market sale Common Stock10b5-1 | -12,396 | $80.12 | $993k | 21,731 | Sep 26, 2025 |
Related signals
Other insiders at Arcellx, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 40Moderate | Arcellx, Inc. | Christopher Heery CHIEF MEDICAL OFFICER | $1.7M 21,034 shares | -97% | |
| 0Weak | Arcellx, Inc. | Christopher Heery CHIEF MEDICAL OFFICER | $5,852 73 shares | -0% | |
| 9Weak | Arcellx, Inc. | Christopher Heery CHIEF MEDICAL OFFICER | $291k 3,643 shares | -10% | |
| 18Weak | Arcellx, Inc. | Kavita Patel director | $101k 1,500 shares | -100% | |
| 47Moderate | Arcellx, Inc. | Michelle Gilson CHIEF FINANCIAL OFFICER | $785k 12,235 shares | -38% | |
| 17Weak | Arcellx, Inc. | Kavita Patel director | $88k 1,500 shares | -100% | |
| 10Weak | Arcellx, Inc. | Kavita Patel director | $96k 1,500 shares | -100% | |
| 9Weak | Arcellx, Inc. | Kavita Patel director | $86k 1,500 shares | -100% | |
| 10Weak | Arcellx, Inc. | Kavita Patel director | $107k 1,500 shares | -100% | |
| 45Moderate | Arcellx, Inc. | Rami Elghandour SEE REMARKS | $2.4M 38,300 shares | -20% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.